Related Experiment Video
Updated: Aug 8, 2026
11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
Summary
Abruptly stopping beta-blockers like propranolol can increase chest pain and cardiac events due to heightened beta-receptor sensitivity. This study investigates this phenomenon with atenolol, pindolol, and propranolol withdrawal in healthy volunteers.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Beta-blocker withdrawal, particularly propranolol, has been linked to increased cardiac events like chest pain, myocardial infarction, and sudden death.
- While some studies suggest withdrawal-induced ischemia is infrequent, others indicate increased beta-receptor sensitivity and potential disease progression.
- Factors like altered oxyhemoglobin dissociation and platelet aggregation may contribute to withdrawal effects.
Purpose of the Study:
- To investigate the sensitivity of beta-receptors following the withdrawal of atenolol, pindolol, or propranolol in normal volunteers.
- To assess whether different beta-blockers have similar withdrawal effects on beta-receptor sensitivity.
Main Methods:
- Normal volunteers received atenolol, pindolol, or propranolol for at least two weeks to achieve maximum exercise tachycardia inhibition.
- Beta-receptor sensitivity was evaluated by measuring responses to isoprenaline injections and exercise tachycardia after drug withdrawal.
Main Results:
- Early observations noted increased chest pain in anginal patients during the first week of propranolol withdrawal.
- Studies show increased beta-receptor sensitivity and responsiveness to isoprenaline after propranolol withdrawal.
- Changes in free triiodothyronine levels have been observed, but catecholamine levels do not appear to be elevated.
Conclusions:
- Beta-blocker withdrawal may lead to increased beta-receptor sensitivity, potentially unmasking underlying disease progression.
- Further research is needed to determine if all beta-blockers exhibit similar withdrawal effects.
- Understanding these withdrawal effects is crucial for patient management and safety when discontinuing beta-blocker therapy.
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...